This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
Males and/or females over age 18
Histologically and/or cytologically documented local advanced or metastatic NSCLC .
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival >=3 months.
Known uncontrolled or symptomatic central nervous system metastatic disease.
Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
Inadequate organ or bone marrow function.
Pregnant or breast-feeding woman.